In the news

“The CHAMPION-AF trial will compare the Watchman FLX device in a head-to-head fashion against best-in-class pharmacological therapy for stroke prevention and evaluate the technology as a first-line therapy for those who can tolerate anticoagulation,” said Ian Meredith, global chief medical officer, Boston Scientific.

How evolving treatment pathways are improving communication and care—both in person and remotely.

HR VP Camille Chang Gilmore explains why Boston Scientific is using data to shine light on healthcare inequality.

Boston Scientific has a plan to tackle systemic racism in healthcare, and to stop the "Black amputation epidemic."

Boston Scientific’s WaveWriter Alpha systems garnered CE Mark approval with indications for managing chronic intractable pain and peripheral nerve stimulation of the trunk for pain management.